Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Rilpivirine/ Emtricitabine/Tenofovir-DF (RPV/FTC/TDF)

Tadalafil (Erectile Dysfunction)

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Emtricitabine and tenofovir-DF do not interact with tadalafil metabolic pathway.

Description:

The interaction between tadalafil and the components of Eviplera has not been studied. Based on data with sildenafil, no dose adjustment is required.
Eviplera Summary of Product Information, Gilead Sciences Ltd, August 2021.

View all available interactions with Rilpivirine/ Emtricitabine/Tenofovir-DF (RPV/FTC/TDF) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.